AJP - Regu AJP: Advances in Physiology Education
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 279: R2237-R2242, 2000;
0363-6119/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (36)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kepka-Lenhart, D.
Right arrow Articles by Morris, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kepka-Lenhart, D.
Right arrow Articles by Morris, S. M., Jr.
Vol. 279, Issue 6, R2237-R2242, December 2000

Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages?

Diane Kepka-Lenhart1, Sanjay K. Mistry1, Guoyao Wu2, and Sidney M. Morris Jr.1

1 Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261; and 2 Department of Animal Science, Texas A & M University, College Station, Texas 77843


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Because arginase hydrolyzes arginine to produce ornithine and urea, it has the potential to regulate nitric oxide (NO) and polyamine synthesis. We tested whether expression of the cytosolic isoform of arginase (arginase I) was limiting for NO or polyamine production by activated RAW 264.7 macrophage cells. RAW 264.7 cells, stably transfected to overexpress arginase I or beta -galactosidase, were treated with interferon-gamma to induce type 2 NO synthase or with lipopolysaccharide or 8-bromo-cAMP (8-BrcAMP) to induce ornithine decarboxylase. Overexpression of arginase I had no effect on NO synthesis. In contrast, cells overexpressing arginase I produced twice as much putrescine after activation than did cells expressing beta -galactosidase. Cells overexpressing arginase I also produced more spermidine after treatment with 8-BrcAMP than did cells expressing beta -galactosidase. Thus endogenous levels of arginase I are limiting for polyamine synthesis, but not for NO synthesis, by activated macrophage cells. This study also demonstrates that it is possible to alter arginase I levels sufficiently to affect polyamine synthesis without affecting induced NO synthesis.

nitric oxide synthase; ornithine decarboxylase; putrescine; RAW 264.7


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

THE AMINO ACID L-arginine is subject to various metabolic fates in its role as precursor for synthesis of nitric oxide (NO), urea, polyamines, proline, glutamate, creatine, agmatine, and proteins (reviewed in Ref. 37). The committed step in the conversion of arginine to polyamines, proline, or glutamate is catalyzed by arginase, which converts L-arginine to L-ornithine and urea. Arginase occurs as two distinct isozymes in mammals; arginase I is cytosolic and normally is expressed almost exclusively in hepatocytes, whereas arginase II is mitochondrial and is expressed at low levels in many cell types (14, 24). The different subcellular location of the two isozymes is thought to play a role in determining whether ornithine becomes converted to polyamines or to glutamate and proline (22, 37).

Recent work has demonstrated that arginase expression, including that of arginase I, can be strongly induced by a variety of cytokines and other stimuli in several nonhepatic cell types, especially macrophages (7, 20, 23, 25, 28). Because arginase I is located in the cytosol, its hydrolysis of arginine to produce ornithine could potentially affect other cytosolic enyzmes such as the nitric oxide synthase (NOS) enzymes or ornithine decarboxylase (ODC) that use arginine or ornithine as substrates. In particular, there is considerable interest in the possibility that arginase I may limit NO production by inducible NOS (iNOS), suggested by reports that inhibition of arginase activity resulted in increased NO production after activation of rat alveolar macrophages (12), murine macrophages, (32), and a murine macrophage cell line (5). However, the arginase(s) expressed in these studies were not identified. Thus the impact of arginase I activity on NO production by activated macrophages remains to be clarified.

Arginase I may also play a role in regulating synthesis of polyamines by macrophages in conditions such as wound healing (29). Previous studies have demonstrated that ODC, generally regarded as the rate-limiting enzyme for polyamine synthesis, is rapidly induced in macrophages and macrophage cell lines by stimuli such as lipopolysaccharide (LPS) or a cAMP analog (26, 31, 34), thus raising the possibility that production of the substrate ornithine via arginase may be an important determinant of polyamine synthesis rates in activated macrophages.

With this background in mind, our objective was to test the hypothesis that arginase I expression is a limiting factor in the synthesis of NO or polyamines by activated macrophages. The RAW 264.7 murine macrophage cell line was selected as the model system for this study because iNOS and ODC can be readily induced in these cells by defined stimuli, and expression of the endogenous arginases in response to these stimuli has been well-characterized (25). To the best of our knowledge, the present study is the first to use gene transfection to manipulate expression specifically of arginase I to study its impact on synthesis of NO and polyamines in activated macrophages. This approach avoids potential pitfalls associated with the use of arginase inhibitors or mixtures of cytokines and other agents to induce arginase, as these interventions may have effects on the treated cells in addition to altering arginase activity or expression. Within the range of arginase I expression achieved in our experiments, we found that arginase I was limiting for synthesis of putrescine and spermidine but was not a determinant of induced NO synthesis by activated murine macrophage cells.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents. Rabbit anti-beta -galactosidase was purchased from Life Technologies. All other reagents were obtained from suppliers identified previously (25).

Expression plasmids. The beta -galactosidase expression plasmid (pEF1/Myc-His/lacZ) containing the Escherichia coli lacZ gene under control of the human EF-1alpha promoter was purchased from Invitrogen. The cDNA for rat arginase I (16) was cloned into the pEF1/Myc-His expression plasmid (Invitrogen) with the use of appropriate restriction sites; no additional epitope sequences were fused to the arginase-coding sequence in this construct.

Cell culture. RAW 264.7 cells were transfected by exposure to a mixture of Lipofectin (Life Technologies) and plasmid DNA (14:1) in serum-free DMEM for 4 h. The cells were returned to DMEM containing 10% fetal calf serum for 24 h before selection in medium containing 1 mg/ml G418. After the first passage, stably transfected cells were maintained in serum-supplemented DMEM containing 500 µg/ml G418, which was always omitted from the medium 2 days before initiating any experimental studies. To initiate all metabolic experiments described here, cells were transferred to DMEM containing 10% dialyzed fetal calf serum (HyClone). LPS (E. coli serotype 111:B4) or 8-bromo-cAMP (8-BrcAMP) was added to confluent cultures (107 cells per well in 6-well culture plate) at final concentrations of 2 µg/ml and 0.5 mM, respectively (25), and incubation was continued for the times indicated.

Assays of arginase activity. Preparation of cell extracts and determinations of arginase-specific activity were as described (25). One milliunit of activity represents hydrolysis of 1 nmol of arginine per minute at 37°C. Arginine hydrolysis by intact cells was determined for cells cultured in a 96-well plate. To each well was added 0.05 µCi of [14C]guanidino-arginine in 150-µl complete DMEM medium containing 10% dialyzed fetal calf serum. Twenty-four hours later, the medium was collected, boiled for 3 min to inactivate enzymes, and conversion of labeled arginine to labeled urea was determined as for the in vitro arginase assay. Results are expressed as percent-labeled arginine hydrolyzed to labeled urea.

Western blotting. Whole cell extracts were prepared in Laemmli sample buffer and used for Western blotting as reported (17, 25).

Measurement of polyamines and nitrite. For determination of polyamines, the entire contents of each well (cells plus medium) were extracted with perchloric acid. After neutralization and removal of insolubles, polyamines (putrescine, spermidine, and spermine) in the extracts were resolved by HPLC and quantified as described previously (38). Blanks consisted of complete medium without cells that were incubated and extracted parallel with the cultured cells. Blank values for each polyamine were subtracted from the polyamine values obtained for the cultured cells. As an index of NO production, nitrite concentrations in conditioned media of cell cultures were determined by the Griess reaction (10). Data were analyzed by the two-tailed paired t-test, with the use of the statistical utilities in the Prism program (GraphPad Software).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

To obtain cell lines expressing varying levels of arginase activity, RAW 264.7 cells were stably transfected to express either rat arginase I (Arg I-RAW) or bacterial beta -galactosidase (lacZ-RAW), the latter representing the control for expression of an unrelated cytosolic protein from the EF-1 plasmid. Expression of these proteins was confirmed by Western blot (Fig. 1). Arg I-RAW migrated as a single band slightly faster than mouse arginase I, which always appears as a closely spaced doublet on Western blots (25). Elevated activity of arginase I in the Arg I-RAW cells was confirmed by in vitro assay and by measuring conversion of labeled arginine to labeled urea by cultured cells. Hydrolysis of arginine to ornithine and urea in cultures of Arg I-RAW cells was 7.2-fold greater than in cultures of lacZ-RAW cells (Fig. 1). It is important to recognize, however, that measurement of arginine hydrolysis to urea in cultured cells underestimates the difference in intracellular arginase activity between the Arg I-RAW and lacZ-RAW cells because of the presence of arginase in fetal calf serum (13). In fact, the arginase activity in cultures of the lacZ-RAW cells is due almost entirely to arginase in the fetal calf serum present in the culture medium (Fig. 1). The specific activity of arginase in extracts of Arg I-RAW cells (17.6 mU/mg) was considerably higher than that of the lacZ-RAW cell extracts (0.1 mU/mg), consistent with the Western blot results.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Arginase expression and activity in RAW 264.7 cells stably transfected with beta -galactosidase (beta -Gal) or rat type I arginase (Arg I). A: Western blots of whole cell lysates. Lane 1: untransfected RAW 264.7 cells; lane 2: bacterial beta -galactosidase RAW 264.7 (lacZ-RAW) cells; lane 3: Arg I RAW 264.7 (Arg I-RAW) cells; and lane M: markers [1-µg whole mouse liver extract, as positive control for Arg I; 9-ng BioRad Broad Range Standard (catalog 161-0317), as positive control for beta -Gal]. Fifty-microgram aliquots of cell lysates were loaded in lanes 1-3. B: relative arginase activity in cultures of lacZ-RAW and Arg I-RAW cells. Hydrolysis of labeled arginine during 24-h culture was measured as described in MATERIALS AND METHODS. Equal numbers of lacZ and Arg I-RAW cells were used for each experiment. Values are means ± SE for 2 independent experiments, with 3 cultures per experiment. For comparison, average hydrolysis of labeled arginine during 24-h incubation in serum-free medium was 0.35%.

To examine the impact of varying arginase I expression on induced NO synthesis, lacZ- and Arg I-RAW cells were treated with interferon-gamma . This stimulus was chosen because it strongly induces iNOS in RAW 264.7 cells without inducing arginase (25). There were no differences in NO production between the two stably transfected cell lines over an eightfold range in arginine concentration (Fig. 2). This was true even at 50 µM arginine, a concentration at which cellular arginine uptake is not maximal because it is below the Km of the y+-transport system (6, 15).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Nitric oxide synthesis by activated lacZ-RAW and Arg I-RAW cells. Cells were treated with 100 U/ml interferon-gamma and incubated for 24 h in DMEM + 10% fetal calf serum at varying arginine concentrations. Results are means ± SE for 3 independent experiments.

We next determined the impact of arginase I expression on polyamine production. The stably transfected RAW 264.7 cell lines were incubated in the presence or absence of LPS and 8-BrcAMP because these agents cause rapid induction of ODC in these cell lines (31, 34). Because LPS also induces expression of iNOS in RAW 264.7 cells, these experiments were conducted at short times after induction to avoid iNOS-dependent inhibition of arginase or ODC activity (2-4). Changes in expression of endogenous arginases are minimal during these brief periods of stimulation (25).

Putrescine concentrations were not significantly different between cultures of unstimulated lacZ-RAW and Arg I-RAW cells at 4 or 6 h (Fig. 3), indicating that arginase I is not limiting for putrescine production in unstimulated RAW 264.7 cells. When cells were treated with LPS or 8-BrcAMP to induce ODC, putrescine production increased in both lacZ-RAW and Arg I-RAW cells. However, putrescine production was appreciably higher in cells treated with 8-BrcAMP than with LPS; at 4 h, the levels were 2.1- and 1.8-fold higher in 8-BrcAMP-treated than in LPS-treated lacZ-RAW and Arg I-RAW cells, respectively, and at 6 h the levels were 1.8- and 1.4-fold higher, respectively. Regardless of the stimulus, there was a significantly greater production of putrescine in Arg I-RAW than in lacZ-RAW cells (Fig. 3). For example, relative to unstimulated controls, 6 h of LPS treatment resulted in 5.4- and 15.9-fold higher putrescine levels in lacZ-RAW and Arg I-RAW cells, respectively, and 6 h of treatment with 8-BrcAMP resulted in 9.7- and 22.1-fold higher levels of putrescine in lacZ-RAW and Arg I-RAW cells, respectively.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Putrescine production in lacZ- and Arg I-RAW cells in the absence (-) or presence (+) of lipopolysaccharide (LPS) (A) or 8-BrcAMP (B). Cells were treated with 2 µg/ml LPS or 0.5 mM 8-BrcAMP for the times indicated. Cell extracts were prepared and analyzed as described in MATERIALS AND METHODS. Values are means ± SE for 4 independent experiments, with 2 cultures per experiment. a: Significantly different (P < 0.05) from corresponding unstimulated cells; b: significantly different (P < 0.05) from lacZ cells stimulated with the same agent.

We also measured levels of polyamines generated by enzymes downstream of ODC. Spermidine levels were not different for unstimulated lacZ-RAW and Arg I-RAW cells at either time point (Fig. 4). Although spermidine levels in Arg I-RAW cells after 6 h of LPS treatment were higher than in the corresponding lacZ-RAW cells, LPS treatment resulted in no statistically significant increase in spermidine concentrations in either lacZ-RAW or Arg I-RAW cells. However, treatment of Arg I-RAW cells with 8-BrcAMP resulted in a 1.5-fold increase in spermidine levels, relative to unstimulated cells, at 4 and 6 h, but no statistically significant change was observed for lacZ-RAW cells (Fig. 4). Thus, when present, increases in spermidine levels were smaller and occurred later than increases in putrescine. The fact that we observed an increase in spermidine levels in 8-BrcAMP-treated cells but not in LPS-treated cells may reflect the fact that putrescine levels increased more rapidly and to a greater degree after 8-BrcAMP treatment than after LPS treatment (Fig. 3). At the time points examined here, there were no significant differences in spermine concentrations for lacZ-RAW and Arg I-RAW cells treated with either agent (not shown).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Spermidine production in lacZ-RAW and Arg I-RAW cells in the absence (-) or presence (+) of LPS (A) or 8-BrcAMP (B). Spermidine concentrations were determined for the same extracts used for putrescine analyses in Fig. 2. Values are means ± SE for 4 independent experiments, with 2 cultures per experiment. a: Significantly different (P < 0.05) from corresponding unstimulated cells; b: significantly different (P < 0.05) from lacZ-RAW cells stimulated with the same agent.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Information on the relationship between arginase expression, especially of arginase I, and NO synthesis in activated macrophages is limited. Chang et al. (5) reported that inhibition of arginase in the LPS-activated J774A.1 murine macrophage line by >5 mM L-norvaline resulted in increased NO production, but the arginase isoform(s) expressed in the J774A.1 cells were not identified [for comparison, only arginase II is expressed in LPS-activated RAW 264.7 cells (25, 35)]. Gotoh and Mori (9) showed that NO production in RAW 264.7 cells treated with LPS + interferon-gamma  + dexamethasone + dibutyryl cAMP was less than in RAW 264.7 cells treated with LPS + interferon-gamma , correlating with increased arginase expression in the former treatment. In this case, however, only arginase II was expressed, and it was not established that the reduced NO production was due only to increased arginase II expression rather than to some other factor, such as a decrease in arginine uptake. Moreover, these results did not match those of Fligger et al. (8), who found no correlation between arginase activity and NO production in murine macrophages and murine macrophage cell lines. The differing results obtained by Gotoh and Mori versus Fligger et al. may reflect differences in the stimuli these groups used to activate the macrophages. More relevant to the current study are the findings of Hey et al. (12) and Tenu et al. (32), who found that inhibition of arginase in activated rat alveolar macrophages or murine peritoneal macrophages, respectively, resulted in increased usage of arginine by iNOS. Although the arginase isoform(s) expressed in these studies were not identified, results of other studies indicate that the activated rat alveolar macrophages probably expressed only arginase I (30) and that the activated murine peritoneal macrophages probably expressed both arginases I and II (21).

Our results, which show no impact of elevated arginase I expression on induced NO synthesis, are consistent with those of Fligger et al. (8) but not with those of Hey et al. (12) and Tenu et al. (32). We wish to note, however, that even though the difference in intracellular arginase activity between the two stably transfected lines in our study was greater than 100-fold, this large difference was due more to the low arginase activity in the lacZ-RAW cells than to a very high level of arginase activity in the Arg I-RAW cells. Our results suggest that a relatively high-threshold level of arginase I activity is required to observe a reduction in NO production, and the arginase I expression in the Arg I-RAW cells simply may have been below this threshold. This proposition is consistent with the mathematical model of Tenu et al. (32) that describes the competition between arginase and iNOS. According to this model, arginase activities in the experiments by Hey et al. (12) and Tenu et al. (32) exceeded the threshold, accounting for differences in their results and those of the present study and of Fligger et al. (8). Taken together, our results and those of previous studies favor the concept that it is not simply the fold-change in arginase activity that is critical for regulation of NO synthesis but rather the level of arginase activity relative to that of iNOS. Further studies using additional cell types are needed to more fully test this notion.

Although regulation of ODC expression in RAW 264.7 cells has been the subject of several studies, there is relatively little information regarding regulation of polyamine production in these cells. The increase in putrescine production and the absence of any increase in spermidine or spermine levels after LPS stimulation of RAW 264.7 cells are consistent with previous findings (34). Tjandrawinata et al. (34) saw no effect of 8-BrcAMP on putrescine production within 4 h, but the difference between their results and ours is likely due to differences in culture conditions. Effects of cAMP analogs on spermidine or spermine production by RAW 264.7 cells have not been reported previously. In any case, the increased putrescine production by LPS- or 8-BrcAMP-treated cells in the present study is entirely consistent with the previously reported induction of ODC by these agents. It is apparent that endogenous levels of arginase in RAW 264.7 cells, together with the arginase present in serum, suffice for putrescine synthesis by unstimulated cells but are insufficient to support maximal rates of putrescine production after induction of ODC.

Taken together with the present results, the occurrence of elevated arginase activities in wounds (1, 29) and tumor cells (e.g., Refs. 11, 18, 19, 27) suggests that arginase I could be a regulator of cellular proliferation. Indeed, increases in arginase I expression are positively correlated with increased proliferation of vascular smooth muscle cells (36). However, elevated arginase expression by itself was not sufficient to boost the proliferation rate of RAW 264.7 cells, a transformed cell line that normally grows rapidly, because Arg I-RAW cells did not proliferate faster than lacZ-RAW cells (not shown). This agrees with the finding that addition of 1 mM ornithine to the culture medium of unstimulated RAW 264.7 cells did not alter their proliferation rate (33). Our results are consistent with the notion that elevated levels of arginase I may be necessary but not sufficient to enhance cell-proliferation rates.

To the best of our knowledge, the present study is the first to demonstrate that the level of arginase I expression can be a determinant of polyamine production in activated macrophages. This is also likely to be true for other cell types. Accordingly, agents that alter arginase I activity or expression should be considered in strategies for modulating polyamine synthesis in clinical and research settings. Importantly, the present study demonstrates that it is possible to alter arginase I levels sufficiently to affect polyamine synthesis without having any effect on induced NO synthesis. Studies are currently underway to determine the impact of altered arginase I and II expression on various aspects of arginine metabolism in additional cell types.


    ACKNOWLEDGEMENTS

This work was supported in part by National Institutes of Health Grant GM-57384 to S. M. Morris. G. Wu is an established investigator of the American Heart Association.


    FOOTNOTES

Address for reprint requests and other correspondence: S. M. Morris, Jr., Dept. of Molecular Genetics and Biochemistry, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA 15261 (E-mail: smorris{at}pitt.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 19 July 2000; accepted in final form 15 August 2000.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Albina, JE, Mills CD, Henry WL, Jr, and Caldwell MD. Temporal expression of different pathways of L-arginine metabolism in healing wounds. J Immunol 144: 3877-3880, 1990[Abstract].

2.   Bauer, PM, Fukuto JM, Buga GM, Pegg AE, and Ignarro LJ. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation. Biochem Biophys Res Commun 262: 355-358, 1999[Web of Science][Medline].

3.   Buga, GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, and Ignarro LJ. Arginase activity in endothelial cells: inhibition by NG-hydroxyarginine during high-output nitric oxide production. Am J Physiol Heart Circ Physiol 271: H1988-H1998, 1996[Abstract/Free Full Text].

4.   Buga, GM, Wei LH, Bauer PM, Fukuto JM, and Ignarro LJ. NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol Regulatory Integrative Comp Physiol 275: R1256-R1264, 1998[Abstract/Free Full Text].

5.   Chang, CI, Liao JC, and Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol Heart Circ Physiol 274: H342-H348, 1998[Abstract/Free Full Text].

6.   Closs, EI. CATs, a family of three distinct mammalian cationic amino acid transporters. Amino Acids (Vienna) 11: 193-208, 1996.

7.   Corraliza, IM, Soler G, Eichmann K, and Modollel M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10, and PGE2) in murine bone marrow-derived macrophages. Biochem Biophys Res Commun 206: 667-673, 1995[Web of Science][Medline].

8.   Fligger, J, Blum J, and Jung TW. Induction of intracellular arginase activity does not diminish the capacity of macrophages to produce nitric oxide in vitro. Immunobiology 200: 169-186, 1999[Web of Science][Medline].

9.   Gotoh, T, and Mori M. Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. J Cell Biol 144: 427-434, 1999[Abstract/Free Full Text].

10.   Green, LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, and Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrite in biological fluids. Anal Biochem 126: 131-138, 1982[Web of Science][Medline].

11.   Harris, BE, Pretlow TP, Bradley EL, Jr, Whitehurst GB, and Pretlow TP, 2d Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 43: 3008-3012, 1983[Abstract/Free Full Text].

12.   Hey, C, Boucher JL, Vadon-Le Goff S, Ketterer G, Wessler I, and Racke K. Inhibition of arginase in rat and rabbit alveolar macrophages by Nomega -hydroxy-D,L-indospicine, effects on L-arginine utilization by nitric oxide synthase. Br J Pharmacol 121: 395-400, 1997[Web of Science][Medline].

13.   Holtta, E, and Pohjanpelto P. Polyamine dependence of Chinese hamster ovary cells in serum-free culture is due to deficient arginase activity. Biochim Biophys Acta 721: 321-327, 1982[Medline].

14.   Jenkinson, CP, Grody WW, and Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 114: 107-132, 1996[Medline].

15.   Kakuda, DK, and MacLeod CL. Na+-independent transport (uniport) of amino acids and glucose in mammalian cells. J Exp Biol 196: 93-108, 1994[Abstract/Free Full Text].

16.   Kawamoto, S, Amaya Y, Murakami K, Tokunaga F, Iwanaga S, Kobayashi K, Saheki T, Kimura S, and Mori M. Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver arginase. J Biol Chem 262: 6280-6283, 1987[Abstract/Free Full Text].

17.   Kepka-Lenhart, D, Chen LC, and Morris SM, Jr. Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. J Leukoc Biol 59: 840-849, 1996[Abstract].

18.   Kocna, P, Fric P, Zavoral M, and Pelech T. Arginase activity determination. A marker of large bowel mucosa proliferation. Eur J Clin Chem Clin Biochem 34: 619-623, 1996[Web of Science][Medline].

19.   Leu, SY, and Wang SR. Clinical significance of arginase in colorectal cancer. Cancer 70: 733-736, 1992[Web of Science][Medline].

20.   Louis, CA, Mody V, Henry WL, Jr, Reichner JS, and Albina JE. Regulation of arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages. Am J Physiol Regulatory Integrative Comp Physiol 276: R237-R242, 1999[Abstract/Free Full Text].

21.   Louis, CA, Reichner JS, Henry WL, Jr, Mastrofrancesco B, Gotoh T, Mori M, and Albina JE. Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension. Am J Physiol Regulatory Integrative Comp Physiol 274: R775-R782, 1998[Abstract/Free Full Text].

22.   Morris, SM, Jr. Arginine synthesis, metabolism, and transport: regulators of nitric oxide synthesis. In: Cellular and Molecular Biology of Nitric Oxide, edited by Laskin JD, and Laskin DL.. New York: Dekker, 1999, p. 57-85.

23.   Morris, SM, Jr. Regulation of arginine availability and its impact on NO synthesis. In: Nitric Oxide: Biology and Pathobiology, edited by Ignarro LJ.. San Diego: Academic, 2000, p. 187-197.

24.   Morris, SM, Jr, Bhamidipati D, and Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression. Gene 193: 157-161, 1997[Web of Science][Medline].

25.   Morris, SM, Jr, Kepka-Lenhart D, and Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol Endocrinol Metab 275: E740-E747, 1998[Abstract/Free Full Text].

26.   Nichols, WK, and Prosser FH. Induction of ornithine decarboxylase in macrophages by bacterial lipopolysaccharides (LPS) and mycobacterial cell wall material. Life Sci 27: 913-920, 1980[Web of Science][Medline].

27.   Rao, KVK, Talageri VR, and Bhide SV. Occurrence of isoenzymes of arginase in mouse lung tumour. Indian J Biochem Biophys 13: 239-241, 1976[Web of Science][Medline].

28.   Salimuddin, Nagasaki A, Gotoh T, Isobe H, and Mori M. Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am J Physiol Endocrinol Metab 277: E110-E117, 1999[Abstract/Free Full Text].

29.   Shearer, JD, Richards JR, Mills CD, and Caldwell MD. Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am J Physiol Endocrinol Metab 272: E181-E190, 1997[Abstract/Free Full Text].

30.   Sonoki, T, Nagasaki A, Gotoh T, Takiguchi M, Takeya M, Matsuzakis H, and Mori M. Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J Biol Chem 272: 3689-3693, 1997[Abstract/Free Full Text].

31.   Taffet, SM, Singhel KJ, Overholtzer JF, and Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 120: 291-300, 1989[Web of Science][Medline].

32.   Tenu, JP, Lepoivre M, Moali C, Brollo M, Mansuy D, and Boucher JL. Effects of the new arginase inhibitor Nomega -hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3: 427-438, 1999[Web of Science][Medline].

33.   Tjandrawinata, RR, and Byus CV. Regulation of the efflux of putrescine and cadaverine from rapidly growing cultured RAW 264.7 cells by extracellular putrescine. Biochem J 305: 291-299, 1995.

34.   Tjandrawinata, RR, Hawel L, 3rd, and Byus CV. Regulation of putrescine export in lipopolysaccharide or IFN-gamma-activated murine monocytic-leukemic RAW 264 cells. J Immunol 152: 3039-3052, 1994[Abstract].

35.   Wang, WW, Jenkinson CP, Griscavage JM, Kern RM, Arabolos NS, Byrns RE, Cederbaum SD, and Ignarro LJ. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem Biophys Res Commun 210: 1009-1016, 1995[Web of Science][Medline].

36.   Wei, LH, Jacobs AT, Morris SM, Jr, and Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 279: C248-C256, 2000[Abstract/Free Full Text].

37.   Wu, G, and Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 336: 1-17, 1998.

38.   Wu, G, Pond WG, Flynn SP, Ott TL, and Bazer FW. Maternal dietary protein deficiency decreases nitric oxide synthase and ornithine decarboxylase activities in placenta and endometrium of pigs during early gestation. J Nutr 128: 2395-2402, 1998[Abstract/Free Full Text].


Am J Physiol Regul Integr Comp Physiol 279(6):R2237-R2242
0363-6119/00 $5.00 Copyright © 2000 the American Physiological Society



This article has been cited by other articles:


Home page
Vet PatholHome page
A. K. Bauer and E. A. Rondini
REVIEW PAPER: The Role of Inflammation in Mouse Pulmonary Neoplasia
Vet. Pathol., May 1, 2009; 46(3): 369 - 390.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
L. D. Nelin, X. Wang, Q. Zhao, L. G. Chicoine, T. L. Young, D. M. Hatch, B. K. English, and Y. Liu
MKP-1 switches arginine metabolism from nitric oxide synthase to arginase following endotoxin challenge
Am J Physiol Cell Physiol, August 1, 2007; 293(2): C632 - C640.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. M. Morris Jr.
Arginine Metabolism: Boundaries of Our Knowledge
J. Nutr., June 1, 2007; 137(6): 1602S - 1609S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. Grasemann, R. Schwiertz, S. Matthiesen, K. Racke, and F. Ratjen
Increased Arginase Activity in Cystic Fibrosis Airways
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1523 - 1528.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
J. K. Stechmiller, B. Childress, and L. Cowan
Arginine Supplementation and Wound Healing
Nutr Clin Pract, February 1, 2005; 20(1): 52 - 61.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. S. Lange, B. Langley, P. Lu, and R. R. Ratan
Novel Roles for Arginase in Cell Survival, Regeneration, and Translation in the Central Nervous System
J. Nutr., October 1, 2004; 134(10): 2812S - 2817S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
N. E. King, M. E. Rothenberg, and N. Zimmermann
Arginine in Asthma and Lung Inflammation
J. Nutr., October 1, 2004; 134(10): 2830S - 2836S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. E. Berkowitz, R. White, D. Li, K. M. Minhas, A. Cernetich, S. Kim, S. Burke, A. A. Shoukas, D. Nyhan, H. C. Champion, et al.
Arginase Reciprocally Regulates Nitric Oxide Synthase Activity and Contributes to Endothelial Dysfunction in Aging Blood Vessels
Circulation, October 21, 2003; 108(16): 2000 - 2006.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. Teixeira, M. L. Santaolaria, V. Meneu, and E. Alonso
Dietary Arginine Slightly and Variably Affects Tissue Polyamine Levels in Male Swiss Albino Mice
J. Nutr., December 1, 2002; 132(12): 3715 - 3720.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. P. Gobert, Y. Cheng, J.-Y. Wang, J.-L. Boucher, R. K. Iyer, S. D. Cederbaum, R. A. Casero Jr., J. C. Newton, and K. T. Wilson
Helicobacter pylori Induces Macrophage Apoptosis by Activation of Arginase II
J. Immunol., May 1, 2002; 168(9): 4692 - 4700.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
H. Li, C. J. Meininger, K. A. Kelly, J. R. Hawker Jr., S. M. Morris Jr., and G. Wu
Activities of arginase I and II are limiting for endothelial cell proliferation
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R64 - R69.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (36)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kepka-Lenhart, D.
Right arrow Articles by Morris, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kepka-Lenhart, D.
Right arrow Articles by Morris, S. M., Jr.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online